文献

J-GLOBAL ID：202002258763761033   整理番号：20A1115091

重症コロナウイルス疾患2019(COVID-19)の治療における抗炎症薬の使用:中国からの臨床免疫学者の展望【JST・京大機械翻訳】

The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China

著者 (20件)： Zhang Wen (Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College Hospital, The Ministry of Education Key Laboratory, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing 100730, China) ,  Zhao Yan (Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College Hospital, The Ministry of Education Key Laboratory, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing 100730, China) ,  Zhang Fengchun (Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College Hospital, The Ministry of Education Key Laboratory, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing 100730, China) ,  Wang Qian (Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College Hospital, The Ministry of Education Key Laboratory, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing 100730, China) ,  Li Taisheng (Clinical Immunology Centre, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100730, China) ,  Li Taisheng (Department of Infectious Disease, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College Hospital, Beijing 100730, China) ,  Li Taisheng (Intensive Care Unit (ICU) for COVID-19, Wu Han Tong Ji Hospital, Wuhan City, Hubei Province 200065, China) ,  Liu Zhengyin (Department of Infectious Disease, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College Hospital, Beijing 100730, China) ,  Liu Zhengyin (Intensive Care Unit (ICU) for COVID-19, Wu Han Tong Ji Hospital, Wuhan City, Hubei Province 200065, China) ,  Wang Jinglan (Department of Respiratory Medicine, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College Hospital, Beijing 100730, China) ,  Wang Jinglan (Intensive Care Unit (ICU) for COVID-19, Wu Han Tong Ji Hospital, Wuhan City, Hubei Province 200065, China) ,  Qin Yan (Department of Nephrology, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College Hospital, Beijing 100730, China) ,  Qin Yan (Intensive Care Unit (ICU) for COVID-19, Wu Han Tong Ji Hospital, Wuhan City, Hubei Province 200065, China) ,  Zhang Xuan (Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College Hospital, The Ministry of Education Key Laboratory, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing 100730, China) ,  Zhang Xuan (Clinical Immunology Centre, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100730, China) ,  Yan Xiaowei (Department of Cardiology, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College Hospital, Beijing 100730, China) ,  Yan Xiaowei (Intensive Care Unit (ICU) for COVID-19, Wu Han Tong Ji Hospital, Wuhan City, Hubei Province 200065, China) ,  Zeng Xiaofeng (Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College Hospital, The Ministry of Education Key Laboratory, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing 100730, China) ,  Zhang Shuyang (Department of Cardiology, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College Hospital, Beijing 100730, China) ,  Zhang Shuyang (Intensive Care Unit (ICU) for COVID-19, Wu Han Tong Ji Hospital, Wuhan City, Hubei Province 200065, China)
資料名： Clinical Immunology  (Clinical Immunology)
巻： 214  ページ： Null  発行年： 2020年 
JST資料番号： A1154A  ISSN： 1521-6616  資料種別： 逐次刊行物 (A)
記事区分： 文献レビュー  発行国： オランダ (NLD)  言語： 英語 (EN)

抄録/ポイント： コロナウイルス病2019(COVID-19)の汎発性発生は世界中で急速に広がっている。中国からの報告は,患者の約20%が重症疾患を発症し,4%の死亡率をもたらしたことを示した。過去2か月において,著者らは,中国の主要なPUMC病院から武漢に至り,最も重篤な患者を治療するために,著者らの同僚を用いて,重要なCOVID-19患者の抗炎症管理に関するMDT(多分野チーム)の複数回の議論に参加した。ここでは,臨床免疫学者の展望から,重症患者の臨床的および免疫学的特徴を考察し,免疫系障害を有する重篤なCOVID-19患者のグルココルチコイド,IL-6拮抗剤,JAK阻害剤およびコレロキン/ヒドロコレロキンを含む抗炎症治療における経験をまとめた。Copyright 2020 Elsevier B.V., Amsterdam. All rights reserved. Translated from English into Japanese by JST.【JST・京大機械翻訳】

シソーラス用語： *消炎作用 ,  *消炎薬 ,  死亡率 ,  グルココルチコイド ,  インターロイキン6
準シソーラス用語： 免疫系 ,  *コロナウイルス ,  アンタゴニスト ,  *免疫学 ,  JAK阻害剤 , 【Automatic Indexing@JST】

著者キーワード (3件)： コロナウイルス病2019(COVID-19) ,  サイトカインストーム ,  抗炎症治療

分類 (2件)： 感染症・寄生虫症一般  (GD01010H) ,  感染症・寄生虫症の治療  (GD01030D)

タイトルに関連する用語 (9件)： 重症 ,  コロナ ,  ウイルス疾患 ,  COVID-19 ,  治療 ,  抗炎症薬 ,  中国 ,  臨床免疫学 ,  展望